Literature DB >> 29535910

Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.

Yan Ting Shue1,2, Jing Shan Lim1,2, Julien Sage1,2.   

Abstract

Small cell lung carcinoma (SCLC) is a fast-growing, highly metastatic form of lung cancer. A major difference between SCLC and other forms of lung cancer is that SCLC tumors often respond well to chemotherapy initially; unfortunately, resistant tumors rapidly recur. In addition, despite a large number of clinical trials with a variety of therapeutic agents, little progress has been achieved in the past three decades in improving the survival of SCLC patients. These clinical observations indicate that SCLC tumors have a high degree of plasticity and rapid adaptability to changes in growth conditions. Here we consider recent evidence pointing to several levels of heterogeneity in SCLC that may explain the ability of these tumors to adjust to different microenvironment and therapeutics. In particular, we review new data pointing to the existence of several subpopulations of tumor cells that interact with each other to promote tumor growth. We also discuss how SCLC tumors that look similar at the histopathological level may actually represent distinct subtypes of tumors and how these differences impact the response to specific therapeutic agents. A better understanding of genetic and cellular heterogeneity will guide the development of personalized approaches to help SCLC patients.

Entities:  

Keywords:  Heterogeneity; knockout mice; neuroendocrine cells; notch, small cell lung cancer (SCLC)

Year:  2018        PMID: 29535910      PMCID: PMC5835592          DOI: 10.21037/tlcr.2018.01.15

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  79 in total

1.  A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Authors:  Helai P Mohammad; Kimberly N Smitheman; Chandrashekhar D Kamat; David Soong; Kelly E Federowicz; Glenn S Van Aller; Jess L Schneck; Jeffrey D Carson; Yan Liu; Michael Butticello; William G Bonnette; Shelby A Gorman; Yan Degenhardt; Yuchen Bai; Michael T McCabe; Melissa B Pappalardi; Jiri Kasparec; Xinrong Tian; Kenneth C McNulty; Meagan Rouse; Patrick McDevitt; Thau Ho; Michelle Crouthamel; Timothy K Hart; Nestor O Concha; Charles F McHugh; William H Miller; Dashyant Dhanak; Peter J Tummino; Christopher L Carpenter; Neil W Johnson; Christine L Hann; Ryan G Kruger
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

2.  Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.

Authors:  Triparna Sen; Pan Tong; Lixia Diao; Lerong Li; Youhong Fan; Jennifer Hoff; John V Heymach; Jing Wang; Lauren Averett Byers
Journal:  Clin Cancer Res       Date:  2017-07-11       Impact factor: 12.531

Review 3.  Cancer immunotherapy targeting the CD47/SIRPα axis.

Authors:  Kipp Weiskopf
Journal:  Eur J Cancer       Date:  2017-03-10       Impact factor: 9.162

4.  Nuclear factor I/B is an oncogene in small cell lung cancer.

Authors:  Alison L Dooley; Monte M Winslow; Derek Y Chiang; Shantanu Banerji; Nicolas Stransky; Talya L Dayton; Eric L Snyder; Stephanie Senna; Charles A Whittaker; Roderick T Bronson; Denise Crowley; Jordi Barretina; Levi Garraway; Matthew Meyerson; Tyler Jacks
Journal:  Genes Dev       Date:  2011-07-15       Impact factor: 11.361

Review 5.  Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Authors:  Suchit H Patel; Andreas Rimner; Roger B Cohen
Journal:  Transl Lung Cancer Res       Date:  2017-04

6.  Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer.

Authors:  Louise Carter; Dominic G Rothwell; Barbara Mesquita; Christopher Smowton; Hui Sun Leong; Fabiola Fernandez-Gutierrez; Yaoyong Li; Deborah J Burt; Jenny Antonello; Christopher J Morrow; Cassandra L Hodgkinson; Karen Morris; Lynsey Priest; Mathew Carter; Crispin Miller; Andrew Hughes; Fiona Blackhall; Caroline Dive; Ged Brady
Journal:  Nat Med       Date:  2016-11-21       Impact factor: 53.440

7.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.

Authors:  Mark D Borromeo; Trisha K Savage; Rahul K Kollipara; Min He; Alexander Augustyn; Jihan K Osborne; Luc Girard; John D Minna; Adi F Gazdar; Melanie H Cobb; Jane E Johnson
Journal:  Cell Rep       Date:  2016-07-21       Impact factor: 9.423

8.  Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma.

Authors:  Hassan Wael; Ryoji Yoshida; Shinji Kudoh; Kohki Hasegawa; Kanako Niimori-Kita; Takaaki Ito
Journal:  Lung Cancer       Date:  2014-05-13       Impact factor: 5.705

9.  Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis.

Authors:  Min-chul Kwon; Natalie Proost; Ji-Ying Song; Kate D Sutherland; John Zevenhoven; Anton Berns
Journal:  Genes Dev       Date:  2015-07-27       Impact factor: 11.361

10.  Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines.

Authors:  Ping Wang; Quanli Gao; Zhenhe Suo; Else Munthe; Steinar Solberg; Liwei Ma; Mengyu Wang; Nomdo Anton Christiaan Westerdaal; Gunnar Kvalheim; Gustav Gaudernack
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more
  18 in total

1.  Modeling heterogeneous tumor growth dynamics and cell-cell interactions at single-cell and cell-population resolution.

Authors:  Leonard A Harris; Samantha Beik; Patricia M M Ozawa; Lizandra Jimenez; Alissa M Weaver
Journal:  Curr Opin Syst Biol       Date:  2019-09-16

2.  Sox2 Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype.

Authors:  Ellen Voigt; Madeline Wallenburg; Hannah Wollenzien; Ethan Thompson; Kirtana Kumar; Joshua Feiner; Moira McNally; Hunter Friesen; Malini Mukherjee; Yohannes Afeworki; Michael S Kareta
Journal:  Mol Cancer Res       Date:  2021-09-30       Impact factor: 6.333

3.  Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer.

Authors:  Shuyue Jiao; Xin Zhang; Dapeng Wang; Hongyong Fu; Qingxin Xia
Journal:  Cancer Manag Res       Date:  2022-04-19       Impact factor: 3.602

4.  Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases.

Authors:  Zoltan Lohinai; Zsolt Megyesfalvi; Kenichi Suda; Tunde Harko; Shengxiang Ren; Judit Moldvay; Viktoria Laszlo; Christopher Rivard; Balazs Dome; Fred R Hirsch
Journal:  Transl Lung Cancer Res       Date:  2019-12

5.  Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.

Authors:  C Allison Stewart; Carl M Gay; Yuanxin Xi; Santhosh Sivajothi; V Sivakamasundari; Junya Fujimoto; Mohan Bolisetty; Patrice M Hartsfield; Veerakumar Balasubramaniyan; Milind D Chalishazar; Cesar Moran; Neda Kalhor; John Stewart; Hai Tran; Stephen G Swisher; Jack A Roth; Jianjun Zhang; John de Groot; Bonnie Glisson; Trudy G Oliver; John V Heymach; Ignacio Wistuba; Paul Robson; Jing Wang; Lauren Averett Byers
Journal:  Nat Cancer       Date:  2020-02-17

Review 6.  Promising Role of Circulating Tumor Cells in the Management of SCLC.

Authors:  Antonella De Luca; Marianna Gallo; Claudia Esposito; Alessandro Morabito; Nicola Normanno
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

7.  Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer.

Authors:  Franziska Böttger; Ekaterina A Semenova; Ji-Ying Song; Giustina Ferone; Jan van der Vliet; Miranda Cozijnsen; Rajith Bhaskaran; Lorenzo Bombardelli; Sander R Piersma; Thang V Pham; Connie R Jimenez; Anton Berns
Journal:  Cell Rep       Date:  2019-06-11       Impact factor: 9.423

8.  Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.

Authors:  Isa Mambetsariev; Tamara Mirzapoiazova; Frances Lennon; Mohit Kumar Jolly; Haiqing Li; Mohd W Nasser; Lalit Vora; Prakash Kulkarni; Surinder K Batra; Ravi Salgia
Journal:  J Clin Med       Date:  2019-07-16       Impact factor: 4.241

9.  The prognostic significance of fibroblast activation protein-α in human lung adenocarcinoma.

Authors:  Jianlin Shi; Zongliu Hou; Jun Yan; Wanfang Qiu; Luxin Liang; Mingyao Meng; Lin Li; Xiaodan Wang; Yanhua Xie; Lihong Jiang; Wenju Wang
Journal:  Ann Transl Med       Date:  2020-03

10.  Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.

Authors:  Triantafyllia Karakousi; Allison L Richards; Metamia Ciampricotti; Àlvaro Quintanal-Villalonga; Angeliki Karatza; Rebecca Caeser; Emily A Costa; Viola Allaj; Parvathy Manoj; Kyle B Spainhower; Faruk E Kombak; Francisco J Sanchez-Rivera; Janneke E Jaspers; Anastasia-Maria Zavitsanou; Danilo Maddalo; Andrea Ventura; William M Rideout; Elliot H Akama-Garren; Tyler Jacks; Mark T A Donoghue; Triparna Sen; Trudy G Oliver; John T Poirier; Thales Papagiannakopoulos; Charles M Rudin
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.